Baotou Dongbao Bio-TechLtd Second Quarter 2024 Earnings: EPS: CN¥0.043 (vs CN¥0.057 in 2Q 2023)
Baotou Dongbao Bio-TechLtd (SZSE:300239) Second Quarter 2024 Results
Key Financial Results
- Revenue: CN¥202.5m (down 22% from 2Q 2023).
- Net income: CN¥25.4m (down 25% from 2Q 2023).
- Profit margin: 13% (in line with 2Q 2023).
- EPS: CN¥0.043 (down from CN¥0.057 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Baotou Dongbao Bio-TechLtd shares are down 1.5% from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. See our latest analysis on Baotou Dongbao Bio-TechLtd's balance sheet health.
Valuation is complex, but we're here to simplify it.
Discover if Baotou Dongbao Bio-TechLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:300239
Baotou Dongbao Bio-TechLtd
Engages in the research and development, production, and sale of gelatin, collagen, and additional products in the People’s Republic of China and internationally.
Excellent balance sheet and good value.